About Tenaya Therapeutics, Inc.
https://www.tenayatherapeutics.comTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms.
CEO
Faraz Ali
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 20
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
COLUMN GROUP LLC
Shares:9.4M
Value:$7.12M
VANGUARD GROUP INC
Shares:5.06M
Value:$3.84M
MILLENNIUM MANAGEMENT LLC
Shares:4.5M
Value:$3.41M
Summary
Showing Top 3 of 99
About Tenaya Therapeutics, Inc.
https://www.tenayatherapeutics.comTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.07M ▼ | $-20.27M ▲ | 0% | $-0.12 ▲ | $-18.41M ▲ |
| Q2-2025 | $0 | $22M ▼ | $-23.28M ▲ | 0% | $-0.14 ▲ | $-21.2M ▲ |
| Q1-2025 | $0 | $27.54M ▲ | $-26.86M ▼ | 0% | $-0.24 ▲ | $-24.88M ▼ |
| Q4-2024 | $0 | $24.65M ▼ | $-23.84M ▲ | 0% | $-0.28 ▲ | $-22.56M ▲ |
| Q3-2024 | $0 | $26.71M | $-25.63M | 0% | $-0.3 | $-24.61M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $56.31M ▼ | $104.98M ▼ | $22.11M ▼ | $82.87M ▼ |
| Q2-2025 | $71.67M ▼ | $122.15M ▼ | $22.32M ▼ | $99.83M ▼ |
| Q1-2025 | $88.16M ▲ | $143.95M ▲ | $24.56M ▼ | $119.4M ▲ |
| Q4-2024 | $61.45M ▼ | $119.94M ▼ | $27.09M ▼ | $92.85M ▼ |
| Q3-2024 | $79.47M | $140.58M | $27.98M | $112.6M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.27M ▲ | $-15.6M ▲ | $8.86M ▼ | $380K ▲ | $-6.36M ▼ | $-15.63M ▲ |
| Q2-2025 | $-23.28M ▲ | $-15.61M ▲ | $24.99M ▲ | $-476K ▼ | $8.9M ▼ | $-15.76M ▲ |
| Q1-2025 | $-26.86M ▼ | $-23.11M ▼ | $22.3M ▲ | $50.26M ▲ | $49.45M ▲ | $-23.5M ▼ |
| Q4-2024 | $-23.84M ▲ | $-18.39M ▲ | $14.1M ▲ | $377K ▲ | $-3.91M ▲ | $-18.59M ▲ |
| Q3-2024 | $-25.63M | $-19.84M | $-30.1M | $31K | $-49.9M | $-20.02M |
CEO
Faraz Ali
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 20
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
COLUMN GROUP LLC
Shares:9.4M
Value:$7.12M
VANGUARD GROUP INC
Shares:5.06M
Value:$3.84M
MILLENNIUM MANAGEMENT LLC
Shares:4.5M
Value:$3.41M
Summary
Showing Top 3 of 99